top of page

Dreamlopments Foundation attended the signing ceremony on the Ravidasvir collaboration



20 March 2024, Dr. Nicolas Durier, General Director of Dreamlopments (DLP) Foundation attended the signing ceremony of the “Collaborative & License Agreement for Ravidasvir” between Pharco Pharmaceuticals (Egypt), Drugs for Neglected Diseases Initiative (DNDi) and the Faculty of Pharmacy of Mahidol University.


Ravidasvir, manufactured by Pharco Pharmaceuticals, is a highly effective drug used to treat hepatitis C infection which is a major public health burden in Thailand. This initiative is supported by the Drugs for Neglected Diseases Initiative (DNDi) which co-signed this agreement.


Furthermore, Ravidasvir is now being used as a key medicine in the C-FREE-CSEA study by Dreamlopments Foundation.


Then Pharco Pharmaceuticals and DNDi colleagues visited the C-FREE-CSEA study Drop-in-Centers Samrong managed by our partner Raks Thai Foundation.



Signing Ceremony of the Collaborative & License Agreement for Ravidasvir


At C-FREE-CSEA study Drop-in-Centers Samrong


At C-FREE-CSEA study Drop-in-Centers Samrong



46 views0 comments

Comments


bottom of page